 |
|
 |
 |

Home > Company Index > Health Products & Services > Medical Laboratories & Research > ILEX Oncology, Inc.
 |
ILEX Oncology, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Ilex Oncology posts widening loss Aug 01 2001 04:47 AM PDT
BTG says gets EU licence for leukemia drug Jul 16 2001 12:02 AM PDT
BTG says gets EU licence for leukemia drug Jul 16 2001 12:02 AM PDT
Millennium & ILEX gets EU license for leukemia drug Jul 12 2001 04:36 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
ILEX Oncology is waging a war on cancer. The company not only provides oncology contract research services to pharmaceutical firms, but it also develops its own drugs for the treatment of the disease. Contract research services, provided through its ILEX Services division, account for almost 90% of sales. Its ILEX Products unit develops drugs for non-Hodgkin's lymphoma, solid tumors, and other forms of cancer; primary product Campath was co-developed with Millennium Pharmaceuticals as a treatment for leukemia. The company is shifting its focus toward the development of drugs and will no longer take new clients for its contract research services. It plans to use ILEX Services solely for its own products.
COMPETITION |
 |
ImmunoGen, Inc. (IMGN)
Maxim Pharmaceuticals, Inc. (MAXM)
SuperGen, Inc. (SUPG)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 27.60
1-Yr. Sales Growth: 54.2%
Employees: 361
Revenue per employee: $76,454.29
KEY PEOPLE |
 |
Richard L. Love
CEO
Gregory L. Weaver
CFO
CONTACT INFO |
 |
4545 Horizon Hill Blvd.
San Antonio, TX 78229
US
Phone: 210-949-8200
Fax: 210-949-8210
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |